ACELYRIN (SLRN) Jefferies Global Healthcare Conference summary

Management and leadership updates

• Recent management changes are primarily internal promotions, maintaining team continuity and operational knowledge.

• The new CEO, Mina Kim, has been with the company since early stages and led key acquisitions.

• CFO and CMO have both joined within the past year, bringing fresh perspectives to the leadership team.

Strategic priorities and capital allocation

• Emphasis on disciplined capital allocation and portfolio prioritization, especially with capital-intensive programs.

• Key data readouts in the third quarter will drive future investment decisions, particularly for HS and lonigutamab.

• The company is well-funded, providing flexibility and time to make data-driven decisions.

Pipeline and clinical development

• Two lead programs, izokibep and lonigutamab, are considered promising, with izokibep seen as approvable in multiple indications.

• HS phase III trial readout moved up to Q3, and additional POC data for lonigutamab expected in the same period.

• Uveitis and axSpA are additional indications under development, with uveitis data expected by year-end.